Safety, Pharmacokinetics and Pharmacodynamics of Oral TLR8 Agonist GS-9688 in Patients with Chronic Hepatitis B: A Randomized, Placebo-Controlled, Double-Blind Phase 1b Study

被引：0
|
作者：
Gane, Edward J. [1 ]
Kim, Hyung Joon [2 ]
Visvanathan, Kumar [3 ]
Kim, Yoon Jun [4 ,5 ]
Nguyen, Anh-Hoa [6 ]
Joshi, Adarsh [6 ]
Reyes, Maribel [7 ]
Lau, Audrey H. [7 ]
Gaggar, Anuj [7 ]
Subramanian, Mani [7 ]
Roberts, Stuart Keith [8 ]
Lim, Young-Suk [9 ]
机构：
[1] Auckland City Hosp, New Zealand Liver Transplant Unit, Auckland, New Zealand
[2] Chung Ang Univ, Coll Med, Seoul, South Korea
[3] St Vincents Hosp Melbourne, Gastroenterol, Fitzroy, Vic, Australia
[4] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[5] Seoul Natl Univ Hosp, Liver Res Inst, Seoul, South Korea
[6] Gilead Sci Inc, Biostat, 353 Lakeside Dr, Foster City, CA 94404 USA
[7] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[8] The Alfred, Dept Gastroenterol, Melbourne, Vic, Australia
[9] Univ Ulsan, Gastroenterol, Asan Med Ctr, Coll Med, Seoul, South Korea
来源：
HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
401
引用
收藏
页码：238A / 239A
页数：2
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF ORAL TLR8 AGONIST GS-9688 IN VIRALLY-SUPPRESSED ADULT PATIENTS WITH CHRONIC HEPATITIS B: A PHASE 2, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED, MULTI-CENTER STUDY
    Gane, Edward J.
    Zhao, Yang
    Tan, Susanna
    Lau, Audrey H.
    Gaggar, Anuj
    Subramanian, Mani
    Kottilil, Shyam
    Tang, Lydia
    [J]. HEPATOLOGY, 2019, 70 : 435A - 436A
  • [2] Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B
    Gane, Edward J.
    Kim, Hyung Joon
    Visvanathan, Kumar
    Kim, Yoon Jun
    Anh-Hoa Nguyen
    Wallin, Jeffrey J.
    Chen, Diana Y.
    McDonald, Circe
    Arora, Priyanka
    Tan, Susanna K.
    Gaggar, Anuj
    Roberts, Stuart K.
    Lim, Young-Suk
    [J]. HEPATOLOGY, 2021, 74 (04) : 1737 - 1749
  • [3] In vitro modulation by TLR8 agonist GS-9688 of multiple regulatory cell types in patients with chronic hepatitis B
    Amin, Oliver E.
    Colbeck, Emily
    Daffis, Stephane
    Pattabiraman, Divya
    Sitali, Colette
    Rosenberg, William
    Fletcher, Simon
    Maini, Mala
    Pallett, Laura J.
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E445 - E445
  • [4] Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators
    Amin, Oliver E.
    Colbeck, Emily J.
    Daffis, Stephane
    Khan, Shahzada
    Ramakrishnan, Dhivya
    Pattabiraman, Divya
    Chu, Ruth
    Steuer, Holly Micolochick
    Lehar, Sophie
    Peiser, Leanne
    Palazzo, Adam
    Frey, Christian
    Davies, Jessica
    Javanbakht, Hassan
    Rosenberg, William M. C.
    Fletcher, Simon P.
    Maini, Mala K.
    Pallett, Laura J.
    [J]. HEPATOLOGY, 2021, 74 (01) : 55 - 71
  • [5] First in Human Study of GS-9688, an Oral Toll-like Receptor 8 (TLR8) Agonist, in Healthy Volunteers: Assessment of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect
    Reyes, Maribel
    Lutz, Justin D.
    Lau, Audrey H.
    Gaggar, Anuj
    Grant, Ethan
    Joshi, Adarsh
    Mackman, Richard L.
    Ling, John
    Mathias, Anita
    German, Polina
    Gane, Edward J.
    [J]. HEPATOLOGY, 2018, 68 : 233A - 233A
  • [6] PERIPHERAL IMMUNE RESPONSES TO TOLL-LIKE RECEPTOR 8 AGONIST GS-9688 IN PATIENTS WITH CHRONIC HEPATITIS B
    Brooks, Anna E.
    Verdon, Daniel
    Eom, Jennifer
    Ng, Jin
    Steemson, John
    Lau, Audrey H.
    Wallin, Jeffrey
    Gaggar, Anuj
    Kottilil, Shyam
    Poonia, Bhawna
    Dunbar, Rod
    [J]. HEPATOLOGY, 2019, 70 : 440A - 441A
  • [7] A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B
    Lim, SG
    Ng, TM
    Kung, N
    Krastev, Z
    Volfova, M
    Husa, P
    Lee, SS
    Chan, S
    Shiffman, ML
    Washington, MK
    Rigney, A
    Anderson, J
    Mondou, E
    Snow, A
    Sorbel, J
    Guan, R
    Rousseau, F
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (01) : 49 - 56
  • [8] Safety, Tolerability, and Exploratory Efficacy of Afimetoran, a TLR7/8 Inhibitor, in Patients with Cutaneous Lupus Erythematosus: A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study
    Hosein, Fareeda
    Ignatenko, Stanislav
    Chadwick, Kristina
    Zhu, Lin
    Baribaud, Frederic
    Bach, Thanh
    Karabeber, Hazem
    Dawes, Michelle
    Carayannopoulos, Leon
    Krishna, Gopal
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 5230 - 5232
  • [9] Preliminary results of a Phase 1b, open-label, multicenter study of selgantolimod (GS-9688) in special populations of patients with chronic hepatitis B
    Agarwal, Kosh
    Cheng, Pin-Nan
    Liu, Chun-Jen
    Duan, Ran
    Kolhatkar, Nikita
    Mateo, Roberto
    Da, Ben
    Richards, Christopher
    Sowah, Leonard
    Fletcher, Simon
    Mendez, Patricia
    Chen, Chi-Yi
    Chuang, Wan-Long
    Holden Hsu, Yao-Chun
    [J]. JOURNAL OF HEPATOLOGY, 2023, 78 : S1159 - S1160
  • [10] Safety and Pharmacodynamics of Oral TLR-7 agonist GS-9620 in patients with Chronic Hepatitis B
    Gane, Edward J.
    Sicard, Eric
    Gordon, Stuart C.
    Gruener, Daniel
    Roberts, Stuart K.
    Kim, Suzanne
    Cheng, Wendy
    Coffin, Carla S.
    Fedorak, Richard
    Kwo, Paul Y.
    Leggett, Barbara A.
    Lau, Daryl
    Lim, Young-Suk
    Pflanz, Stefan
    Massetto, Benedetta
    Subramanian, Mani
    McHutchison, John G.
    Freilich, Bradley
    Visvanathan, Kumar
    [J]. HEPATOLOGY, 2013, 58 : 661A - 662A
12345